Exocrine Pancreatic Insufficiency Therapeutics Market by Top Key Players are AzurRx, AbbVie Inc., CHIESI Farmaceutici S.p.A., Allergan, Janssen Pharmaceuticals, Inc. Forecast to 2026
The global exocrine pancreatic insufficiency therapeutics market to reach USD 2.55 billion by 2026, exhibiting a CAGR of 6.5% during the forecast period. Increasing prevalence of diabetes worldwide is touted to be one of the core factors fueling the growth of this market. According to the International Diabetes Federation (IDF), in 2019, approximately 463 million adults were suffering from diabetes and by 2045, this figure will rise to 700 million. In the same year, the disease caused deaths of 4.2 million people and around 374 million people are at an increased risk of developing type 2 diabetes. Diabetes cause microvascular damage which reduce pancreatic volume, inducing pancreatic fibrosis. According to the National Institutes of Health, those afflicted by type 1 diabetes have a 30 to 50% chance of developing exocrine pancreatic insufficiency, while those with type 2 have a 20 to 30% chance of developing the disorder. Thus, the exocrine pancreatic insufficiency therapeutics market stands to gain as a result.
Request a Sample Copy of Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/exocrine-pancreatic-insufficiency-market-100652
Steady Rise in the Incidence of Disorders Associated with EPI to Aid Growth
There are many conditions associated with exocrine pancreatic insufficiency such as celiac disease, cystic fibrosis, inflammatory bowel diseases, and pancreatic cancer. The prevalence of these associated disorders is on the rise, which is expected to ramp up the demand for exocrine pancreatic insufficiency treatment. This increasing demand has led to innovation in EPI medications and therapeutics that have enhanced the potential of this market. One of the most popular development in the market is the creation of the Pancreatic Enzyme Replacement Therapy (PERT) which is furthering the exocrine pancreatic insufficiency therapeutics market trends.
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/exocrine-pancreatic-insufficiency-market-100652
Increasing Incidence of Gastrointestinal Disorders to Drive the Market in North America
Among regions, North America is slated to dominate the exocrine pancreatic insufficiency therapeutics market share in the forecast period, having generated USD 1.18 billion in 2018 in revenue. The main reasons for this is the increasing prevalence and awareness regarding gastrointestinal diseases in the region along with a high adoption rate of advanced treatment methods for EPI. Rising disposable incomes that have increased the uptake of EPI therapeutics would aid Asia-Pacific register the highest growth rate in this market. Awareness about associated disorders is growing speedily in countries such as Japan and India which will feed the market in the region. In Europe, the market is anticipated to be driven by the increasing penetration of exocrine pancreatic insufficiency medications.
Table of Content from Exocrine Pancreatic Insufficiency Therapeutics Market:
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. Key Insights
4.1. Prevalence of Major Disorders Associated With Exocrine Pancreatic Insufficiency
4.2. Pipeline Analysis
4.3. Recent Industry Developments Such as Mergers, Partnerships & Acquisitions
4.4. Regulatory Scenario
4.5. New Product Launches
5. Global Exocrine Pancreatic Insufficiency Therapeutics Market Analysis, Insights and Forecast, 2015-2026
5.1. Key Findings / Summary
5.2. Market Analysis, Insights and Forecast – By Therapy
5.2.1. Pancreatic Enzyme Replacement Therapy (PERT)
5.2.2. Nutritional Therapy
5.3. Market Analysis, Insights and Forecast – By Distribution Channel
5.3.1. Hospital Pharmacies
5.3.2. Retail Pharmacies & Drug Stores
5.4. Market Analysis, Insights and Forecast – By Country
5.4.1. North America
5.4.3. Asia Pacific
5.4.4. Rest of the World
6. North America Exocrine Pancreatic Insufficiency Therapeutics Market Analysis, Insights and Forecast, 2015-2026
6.1. Key Findings / Summary
6.2. Market Analysis – By Therapy
6.2.1. Pancreatic Enzyme Replacement Therapy (PERT)
6.2.2. Nutritional Therapy
6.3. Market Analysis – By Distribution Channel
6.3.1. Hospital Pharmacies
6.3.2. Retail Pharmacies & Drug Stores
6.4. Market Analysis – By Country
Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights, we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Fortune Business Insights Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune – 411045, Maharashtra, India.
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: [email protected]
Linkedin | Twitter | BLogs
This release was published on openPR.
Originally Published on : https://www.openpr.com/news/2126070/exocrine-pancreatic-insufficiency-therapeutics-market-by-top
Contact/WhatsAPP: +91 7827887720 EMAIL: [email protected]
Disclaimer: The perspectives communicated in the article/news/press release above are those of the writers’ and don’t really speak to or mirror the perspectives of this website or its personnel. Except if in any case noticed, the writer is writing in his/her own ability. They are not expected and ought not to be thought to speak to legitimate thoughts, perspectives, or strategies of any individual, Institution, organization or foundation.